



Resource impact template

Resource impact

Published: 28 January 2026

www.nice.org.uk

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for relapsing forms of multiple sclerosis:

- [Natalizumab \(originator and biosimilar\) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy](#) (2026) NICE technology appraisal guidance 1126
- [Cladribine for treating active relapsing forms of multiple sclerosis](#) (2025) NICE technology appraisal guidance 1053
- [Ublituximab for treating relapsing multiple sclerosis](#) (2024) NICE technology appraisal guidance 1025